Comparative Pharmacology
Head-to-head clinical analysis: NORINYL 1 80 21 DAY versus OVCON 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL 1 80 21 DAY versus OVCON 50.
NORINYL 1+80 21-DAY vs OVCON-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and alters cervical mucus and endometrial lining.
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days followed by 7 days of placebo or no tablets.
None Documented
None Documented
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Norethindrone: 5-14 hours (terminal); ethinyl estradiol: 7-20 hours. Clinical context: Steady-state reached within 5-7 days; half-life allows once-daily dosing with stable contraceptive efficacy.
Renal (40-60% as metabolites), fecal (20-30%)
Renal: 40-60% (metabolites, primarily glucuronide conjugates; <1% unchanged). Fecal: 30-50% (via biliary elimination).
Category C
Category C
Oral Contraceptive
Oral Contraceptive